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immobilization. She was readmitted 2  months later with 
septic shock and bilateral septic arthritis needing right 
hip replacement for source control. She developed multiple 
contractures of lower extremities due to prolonged immo-
bility and was immobile for a total of 11 months despite sig-
nificant physical therapy (PT) involvement. A few months 
into her hospital stay, she developed acute onset right ankle 
pain with no falls or trauma. Xrays showed right tibial 
metaphyseal fracture and severe demineralization of bones 
of lower extremities. History and physical exam showed 
no signs/symptoms of malabsorption, hyperthyroidism or 
Cushing’s syndrome. Laboratory evaluation showed cal-
cium (Ca) of 11.8 mg/dL (8.5–10.4), parathyroid hormone 
(PTH) < 3  ng/dL (12–72), C-telopeptide (Ctx) 1806 pg/ml 
(60–650) and normal phosphate, TSH, prolactin, 25-hydroxy 
and 1,25-dihydroxy vitamin D levels. PTHrP (parathyroid 
hormone related peptide) was < 2 pmol/L. 24-hour urine Ca 
was 414 mg (50–150). Serum and urine protein electropho-
resis showed no monoclonal spike. Gonadal profile showed 
estrogen 42 pg/dL, FSH 1 mU /mL, LSH 0.1 mU /mL. DEXA 
scan showed severe osteoporosis with T-score of -3.2 at both 
the left femoral neck and lumbar spine. Osteoporosis and 
hypercalcemia were attributed to protracted immobiliza-
tion. Therapy was initiated with alendronate 70 mg weekly 
along with vitamin D.  Teriparatide was not used due to 
high serum Ca. Repeat labs at 6 months showed good re-
sponse to alendronate with Ca 9.6, PTH 58, 24 hr urine Ca 
96 and Ctx 1092. Mobilization of patient and regular PT 
were performed.
Conclusion:
Osteoporosis in a young adult is a rare entity and demands 
evaluation for secondary causes. An important and 
overlooked cause of bone loss is immobility and decreased 
load development on bones. Bone is a piezoelectric mate-
rial and immobilization causes negative bone turnover. 
Early physical mobility and weight bearing is the most ef-
fective method of reducing bone loss. Teriparatide, due to 
anabolic effects has an advantage over bisphosphonates. 
Romosozumab (anti-sclerostin antibody) and whole body 
vibration are also being studied for disuse osteoporosis. 
Calcium and vitamin D supplementation are essential.
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Abstract:
Objective: Saline suppression testing (SST) and captopril 
challenge test (CCT) are commonly used confirmatory tests 
for primary aldosteronism (PA). Seated SST (SSST) is re-
ported to be superior to recumbent SST (RSST). Whether 
SSST is better than CCT remains unclear. Therefore we 
conducted a prospective study to compare the diagnostic ac-
curacy of SSST and CCT.
Methods: Hypertensive patients with high risk of PA were 
consecutively included. Patients with aldosterone-renin 
ratio≥1.0 ng•dl-1/μIU•ml-1 were asked to complete SSST, 
CCT and fludrocortisone suppression test (FST). Using 
FST as the reference standard (plasma aldosterone con-
centration [PAC] post-FST ≥6.0 ng•dl-1), area under the 
receiver-operator characteristic curves (AUC), sensitivity 
and specificity of SSST and CCT were calculated, and mul-
tiple regression analyses were conducted to identify poten-
tial factors for false diagnosis.
Results: A total of 183 patients diagnosed as PA and 48 as 
essential hypertension completed the study. Using PAC 
post-SSST and PAC post-CCT to confirm PA, SSST and 
CCT had comparable AUCs (AUCSSST 0.83 [0.78,0.88] 
vs. AUCCCT 0.86 [0.81,0.90], P=0.308). Setting PAC post-
SSST and post-CCT at 8.5 ng•dl-1 and 11 ng•dl-1, respec-
tively, the sensitivity and specificity of SSST [0.71 (95%CI 
0.64 to 0.77) and 0.82(0.68,0.90)] and CCT [0.73(0.66,0.79) 
and 0.80(0.66,0.89)] were not significantly different. In the 
multiple regression analyses, 1SD increment of sodium in-
take resulted in 40% lower risk of false diagnosis in SSST.
Conclusions: SSST and CCT have comparable diagnostic 
accuracy. Insufficient sodium intake decreases the diag-
nostic efficiency of SSST but not CCT. Since the CCT is 
simpler and cheaper, it is preferable to the SSST.
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The results of a number of studies have shown that in ar-
terial hypertension (AH), G/T and T/T genotypes of the 
adiponectin gene (ADIPOQ) and Gly/Arg and Arg/Arg 
genotypes of the insulin receptor substrate 1 gene (IRS-1) 
are associated with a greater severity of metabolic disorders 
and hemodynamic parameters compared with G/G and Gly/
Gly genotypes of these genes.
The aim of the study: to evaluate the severity of cardiovas-
cular remodeling and metabolic disorders in hypertensive 
obese patients in the simultaneous presence of two unfa-
vorable genotypes of the ADIPOQ and IRS-1 genes.
Methods: We examined 300 AH patients: 200 patients with 
AH and obesity, 50 patients with AH and normal body 
weight, 50 patients with AH and overweight, 40 patients 
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healthy individuals. The polymorphisms of the ADIPOQ 
and IRS-1 was assessed by molecular genetic method.
Results: It was found that in all groups of hyperten-
sive patients, regardless of body weight and the presence 
of DM2, the simultaneous presence of two unfavorable 
genotypes of the ADIPOQ and IRS-1 genes occurred signif-
icantly more often than in healthy individuals: in 41% of 
AH patients with obesity, 30% of AH patients with normal 
weight, 40% of AH with overweight, 57.5% of AH with obe-
sity and DM2 vs. 13.3% of healthy individuals. In hyperten-
sive patients, in the presence of overweight and obesity, the 
frequency of combination of the two unfavorable genotypes 
of these genes was significantly higher than in AH patients 
with normal body weight.
Conducting comparative evaluation of AH patients with 
obesity depending on the presence of two unfavorable 
genotypes or two protective genotypes of the ADIPOQ and 
IRS-1 genes showed that carriers of the combination of 
the G/T + T/T genotype of the ADIPOQ and the Gly/Arg 
+ Arg/Arg genotype of the IRS-1 had a higher body mass 
index, more pronounced insulin resistance, cardiovascular 
remodeling, adipokine imbalance, impaired carbohydrate 
and lipid metabolism.
Conclusions: In AH patients, the frequency of the simul-
taneous presence of two unfavorable polymorphisms of 
ADIPOQ and IRS-1 genes was higher than in healthy 
individuals. In AH patients with overweight and obe-
sity, the frequency of combination of the two unfavorable 
genotypes of the ADIPOQ and IRS-1 genes was signifi-
cantly higher than in normal body weight. The presence of 
a combination of two unfavorable genotypes of the ADIPOQ 
and IRS-1 genes in patients with AH and obesity was asso-
ciated with a greater severity of cardiovascular remodeling 
and metabolic disorders compared with the combination of 
two protective genotypes of these genes.
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Background: Dulaglutide (DU) was superior to pla-
cebo (PL) in reducing the incidence of Major Adverse 
Cardiovascular Events in the Researching Cardiovascular 
Events with a Weekly INcretin in Diabetes (REWIND 
Study) broad patient population. The safety of DU 
treatment is also of interest to health care providers who 
treat an older patient population (≥65 years of age).
Aims: The primary objective of this post-hoc analysis was 
to evaluate DU safety in the REWIND patient subgroup 
populations categorized by age (≥ 65 and < 65 years) with 
regards to the occurrence of the composite safety outcome 
of overall mortality and severe hypoglycemia. One of the 
key secondary objectives was first occurrence of severe 
hypoglycemia.
Methods: Patients were grouped into two age groups: 
≥65 and <65  years. Time-to-event for the composite 
safety endpoint as well as individual variables were 
analyzed using Cox proportional hazards regression. 
Hazard ratios (HRs) and 95% confidence intervals (CIs) 
for between group treatment differences were also 
calculated.
Results: Of the 9,901 patients randomized in REWIND, a 
total of 5,256 (DU, 2,619; PL, 2,637) were aged ≥65 years. 
The incidence of the composite safety outcome for patients 
aged ≥65  years was 399 of 2619 (15.2%) for DU-treated 
patients and 425 of 2,637 (16.1%) for PL-treated patients. 
The incidence of the composite safety outcome for those 
aged <65  years was 188 of 2,330 (8.1%) for DU-treated 
patients and 224 of 2,315 (9.7%) for PL-treated patients. 
Between group treatment differences (HR [95% CI]) were 
0.94 (0.82, 1.08) for patients ≥65  years of age and 0.82 
(0.68, 1.00) for patients <65  years of age; interaction 
p-value  =  0.277. The incidence of the secondary outcome 
of first occurrence of severe hypoglycemia for patients aged 
≥65 years was 46 of 2619 (1.8%) for DU-treated patients 
and 49 of 2,637 (1.9%) for PL-treated patients. The inci-
dence of this outcome for patients <65 years was 18 of 2,330 
(0.8%) for DU-treated patients and 25 of 2,315 (1.1%) for 
PL-treated patients. Between group treatment differences 
(HR [95% CI]) were 0.95 (0.63, 1.42) for patients ≥65 years 
of age and 0.71 (0.39, 1.31) for patients <65 years of age; 
interaction p-value = 0.443. The safety profile of DU was 
reviewed based upon the results of subgroup analysis of 
treatment emergent adverse events and serious adverse 
events by preferred terms for comparing PL and DU for 
age subgroups (≥65 years of age versus <65 years). None 
of the results indicated that DU has a different safety pro-
file across the age subgroups evaluated in this post-hoc 
analysis.
Conclusions: Treatment with DU demonstrated sim-
ilar safety in REWIND patients aged ≥65  years and 
those aged <65  years. Dulaglutide can be considered 
a safe and effective treatment option for use in older 
adults.
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